X

pharmaceuticals

BIIB Earnings: A snapshot of Biogen’s Q2 2023 financial results

Biotechnology firm Biogen Inc. (NASDAQ: BIIB) reported lower earnings, on an adjusted basis, and revenues for the second quarter of…

A look at the factors that influenced UnitedHealth’s Q2 earnings

Health insurance company UnitedHealth Group (NYSE: UNH) reported strong second-quarter results last week, triggering a stock rally. The company also…

Earnings Preview: Here’s what to expect from Johnson & Johnson’s Q2

Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) entered a new phase recently after spinning off its consumer business. The move…

Infographic: Highlights of UnitedHealth Group’s (UNH) Q2 2023 earnings

Diversified healthcare company UnitedHealth Group (NYSE: UNH) reported higher earnings and revenues for the second quarter of 2023. The company…

Earnings: AngioDynamics (ANGO) reports higher adj. profit for Q4; revenue up 5%

Medical device company AngioDynamics Inc. (NASDAQ: ANGO) on Wednesday reported an increase in adjusted profit for the fourth quarter of…

Ocean Biomedical focuses its malaria program to address chronic malaria crisis in sub-Saharan Africa

Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said it is focusing its multi-pronged malaria program to address the…

Apogee Therapeutics set to go public. Here’s what you need to know

The US IPO market has remained mostly sluggish so far this year, continuing the weakness experienced in 2022. Meanwhile, there…

Rite Aid Corp. (RAD) Q1 2024 adj. loss narrows; revenue down 6%

Drugstore chain Rite Aid Corporation (NYSE: RAD) announced first-quarter results, reporting lower revenues and a narrower adjusted loss. First-quarter loss,…

Walgreens Boots Alliance (WBA) Q3 adj. profit rises on higher revenues

Walgreens Boots Alliance, Inc. (NASDAQ: WBA) on Tuesday said its third-quarter sales rose 9%. As a result, the healthcare service…

Superlatus names Dr. Eugenio Bortone COO; interim CEO Tim Alford to become CCO

Superlatus, Inc., a holding company of food products and distribution capabilities, on Tuesday, announced new appointments to its management team.…

Ocean Biomedical (OCEA) joins the Russell 2000 Index

Ocean Biomedical, Inc. (NASDAQ: OCEA) on Tuesday said it has been included in the Russell 2000 Index and the broad-market…

Ocean Biomedical granted US patent for bispecific cancer immunotherapy treatment

Biotechnology company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Monday said its scientific co-founder Dr. Jack Elias has been granted a…

Superlatus to be acquired by TRxADE HEALTH to create a global food consolidation platform

Superlatus, Inc., a U.S.-based holding company of food products and distribution capabilities, has signed a letter of intent to be…

Ocean Biomedical extends patent rights for idiopathic pulmonary fibrosis discovery to Europe

Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Friday revealed that its scientific co-founder Dr. Jack Elias has received notice…

Fundamental Research Corp. raises Ocean Biomedical’s price target to $17.63 per share

Ocean Biomedical, Inc. (NASDAQ: OCEA) on Wednesday said that Fundamental Research Corp. increased the price target of the company’s stock…

Earnings Summary: A snapshot of Catalent’s Q3 2023 results

Catalent, Inc. (NYSE: CTLT), a provider of delivery technologies and development solutions to the pharmaceutical industry, has reported earnings for…

Ocean Biomedical’s scientific co-founder Dr. Jonathan Kurtis gets new patent for malaria vaccine

Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company focused on clinical programs in oncology, fibrosis, and infectious disease, Thursday said…

Earnings Summary: CooperCompanies (COO) reports Q2 2023 financial results

Medical device maker CooperCompanies (NYSE: COO) has announced financial results for the second quarter of 2023, reporting lower earnings despite…

Taglich Brothers initiates coverage of Ocean Biomedical, with price target of $20

Biopharma company Ocean Biomedical, Inc. (NASDAQ: OCEA) on Thursday revealed that Taglich Brothers initiated coverage on the company with a…

Ocean Biomedical, Inc. (NASDAQ: OCEA) Research Summary

Ocean Biomedical, Inc. (NASDAQ: OCEA) is a biopharmaceutical company focused on clinical programs in oncology, fibrosis, infectious disease, and inflammation.…

Ocean Biomedical (OCEA) set to join the Russell 2000 Index

Biopharmaceutical company Ocean Biomedical (NASDAQ: OCEA) on Thursday said it is expected to be added to the Russell 2000 Index,…